跳至主要内容
临床试验/NCT03827031
NCT03827031招募中不适用

Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients

Centre Hospitalier Universitaire de Nīmes10 个研究点 分布在 1 个国家目标入组 297 人开始时间: 2022年7月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
297
试验地点
10
主要终点
Change in iatrogenic drug risk in intervention groups versus control group

研究概览

简要总结

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient (or their representative) has given his consent and signed the consent form.
  • The patient is affiliated to a health insurance programme.
  • The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
  • The patient is available for a follow-up of 3 months.
  • The patient is hospitalized in the surgery department.
  • Patient with a Trivalle score greater than or equal to 2 (≥).
  • Patient living in a nursing home or going back home after hospitalization.

排除标准

  • The subject is participating in another category I interventional study.
  • The subject is in an exclusion period determined by another study.
  • The subject is under safeguard of justice.
  • It is not possible to give the patient (or his/her trusted-person) informed information.
  • Palliative care

结局指标

主要结局

Change in iatrogenic drug risk in intervention groups versus control group

时间窗: 3 months after hospitalization

Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)

次要结局

  • Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group(Hospital discharge (maximum 30 days))
  • Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent(3 months after hospital discharge)
  • Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)(Hospital discharge (maximum 30 days))
  • Time required for ransmitting multidisciplinary correspondence documents in B2 group(Hospital discharge (maximum 30 days))
  • Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group(2 months post discharge)
  • Mortality rate in each group(3 months after hospital discharge)
  • Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group(Hospital discharge (maximum 30 days))
  • Rate of patients with at least one rehospitalization in each group(3 months after hospital discharge)
  • patient satisfaction in all groups (A, B1, B2)(3 months after hospital discharge)
  • Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups(Hospital discharge (maximum 30 days))
  • Number of potentially inappropriate medications per patient in each group(3 months after hospital discharge)
  • Number of multidisciplinary correspondence documents sent to the community acotors in B2 group(Hospital discharge (maximum 30 days))
  • Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2(2 months post hospital discharge)
  • Healthcare team satisfaction in interventional groups (B1, B2)(3 months after hospital discharge)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验

Impact of Mulstidisciplinary Medication Assessment... | 临床试验